Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study reveals best commercial weight loss program for quick results

NCT ID NCT06972277

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared three commercial weight management programs to see which helps adults with overweight or obesity lose the most weight in 12 weeks. 459 participants were randomly assigned to one of the programs. The main goal was to measure weight change and percentage of body weight lost.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
commercial weight management program (behavioral/lifestyle support)
What this could lead to
If successful, this could help identify which commercial weight loss program works best for short-term weight loss in adults with overweight or obesity.
What could go wrong
This is a completed study with 459 participants, but results may not apply to everyone. Weight loss at 12 weeks may not be sustained long-term, and individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

459 people

The number who actually took part.

Started

May 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * BMI ≥27 kg/m² * Own a bodyweight scale that they can weigh themselves with during the study * Willing and able to comply with study protocol * Capable of providing informed consent * Able to read and write in English * Willing to be randomized * Willing to sign a Non Disclosure Agreement Exclusion Criteria: * Pregnant, lactating, or plans to become pregnant in the next 6 months * Previous bariatric surgery or planned bariatric surgery during the study period * Major surgery within the past 6 months or plans to have surgery during the study period * Participation in the previous 3 months or current participation in a structured behavioral weight loss program * Participation in another structured weight loss program during the study period (i.e., the next 3 months) * Communication needs that would render them unable to understand the study and/or intervention materials * Current or previous history of anorexia or bulimia nervosa * Engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight * Currently taking anti-obesity medications, planning to take anti-obesity medications in the next 6 months, or previously taken anti-obesity medications in the previous 3 months * Weight loss of ≥ 5 kg (11 lb) in the previous 6 months * Self-reported diagnosis of severe depression, bipolar disorder, substance abuse, or psychosis * Participants who are involved in any other research studies at this time * Untreated thyroid disease or any changes (type or dose) in thyroid medication in last 6 months * Chronic/inflammatory gastrointestinal disorders (irritable bowel syndrome is acceptable) * History of heart problems (e.g., angina, bypass surgery, myocardial infarction, etc.) within previous 6 months * Diagnosis of type 1 or type 2 diabetes * Presence of implanted cardiac defibrillator or pacemaker * History of cancer within past 5 years or current treatment for cancer * Hospitalization for psychiatric disorders during the last 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • WW International, Inc

    New York, New York, 10010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.